Keyphrases
Adverse Effects
100%
Clinical Application
100%
Treatment Management
100%
Response Predictors
100%
Ribavirin
100%
Treatment Length
100%
Telaprevir
100%
Stopping Rule
100%
Pegylated Interferon
75%
Anemia
50%
Hepatitis C Virus RNA
50%
Triple Therapy
50%
Skin Rash
50%
Rapid Viral Response
50%
Cirrhosis
25%
Nave
25%
Chronic Hepatitis C Virus Infection
25%
Clinical Significance
25%
Treatment Cessation
25%
Fibrosis Stage
25%
Treatment Duration
25%
Cirrhotic Patients
25%
Sustained Viral Response
25%
Short-term Treatment
25%
Close Monitoring
25%
Null Responder
25%
Early Cessation
25%
Pegylated Interferon Therapy
25%
Futility Rules
25%
Selecting Candidates
25%
Medicine and Dentistry
Treatment Response
100%
Ribavirin
100%
Peginterferon
100%
Telaprevir
100%
Adverse Effect
100%
Anemia
50%
Virus RNA
50%
Hepatitis C Virus
50%
Exanthem
50%
Fibrosis
25%
Recurrent Disease
25%
Chronic Hepatitis C
25%
Combination Therapy
25%
Liver Cirrhosis
25%
Treatment Duration
25%
Clinical Significance
25%
Pharmacology, Toxicology and Pharmaceutical Science
Ribavirin
100%
Peginterferon
100%
Telaprevir
100%
Hepatitis C Virus
50%
Virus RNA
50%
Anemia
50%
Rash
50%
Combination Therapy
25%
Fibrosis
25%
Liver Cirrhosis
25%
Chronic Hepatitis C
25%
Recurrent Disease
25%